Results 1 to 10 of about 3,235 (226)

Short-term therapeutic effectiveness of tezepelumab in patients with severe asthma: A real-world study

International Immunopharmacology
BACKGROUND Tezepelumab is a fully human monoclonal antibody which specifically binds to thymic stromal lymphopoietin (TSLP), thus effectively inhibiting its pleiotropic pathogenic actions.
Alessandro Vatrella, Girolamo Pelaia, Enrico Iaccino   +2 more
exaly   +3 more sources

Tezepelumab in severe asthma with pulmonary mucus plugs and eosinophilic chronic rhinosinusitis after dupilumab intolerance and suboptimal mepolizumab response: A case report [PDF]

Respiratory Medicine Case Reports
Background: Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), has demonstrated efficacy in the treatment of severe asthma and chronic rhinosinusitis with nasal polyps.
Satoru Senoo, Kei Fukushima, Kohei Takata, Shunsuke Matsumori, Takahiro Baba, Yuka Sugisaki, Hiroki Omori, Hiroaki Matsuura, Akihiko Taniguchi, Rika Omote, Nobuaki Miyahara, Toshiaki Okada   +11 more
doaj   +2 more sources

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies

Pulmonary Therapy
Introduction This post hoc analysis assessed the ability of tezepelumab treatment to restore normal lung function in patients with severe, uncontrolled asthma with abnormal lung function at baseline pooled from the PATHWAY and NAVIGATOR studies.
Ian D. Pavord, Christopher E. Brightling, Stephanie Korn, Nicole L. Martin, Sandhia S. Ponnarambil, Nestor A. Molfino, Jane R. Parnes, Christopher S. Ambrose   +7 more
doaj   +2 more sources

Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort

ERJ Open Research
Background Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, has demonstrated efficacy for severe asthma in clinical trials, but real-world evidence remains limited.
Jasmin Khateeb, Mordechai R. Kramer, Ophir Freund, Reem Mhameed, Eviatar Naamany, Aviv Kupershmidt, Gal Elkayam, Anna Breslavsky, Dror Rosengarten, Yaniv Dotan, Ori Wand, Amir Bar-Shai   +11 more
doaj   +2 more sources

Tezepelumab: redefining TSLP blockade in severe asthma through mechanistic precision and translational pharmacology [PDF]

Frontiers in Pharmacology
Approximately 40%–50% of patients prescribed GINA Step 4–5 ICS/LABA therapy remain inadequately controlled, and existing biologics are restricted by phenotypic eligibility criteria that exclude the substantial type 2-low patient population.
Ghaith K. Mansour, Santosh Kumar, Hatouf H. Sukkarieh   +2 more
doaj   +2 more sources

Tezepelumab for Patients with Severe Uncontrolled Asthma: A Systematic Review and Meta-Analysis

Journal of Asthma and Allergy, 2022
Zaid Zoumot,1 Nasser Al Busaidi,2 Wail Tashkandi,3 Ahmed A Aljohaney,4 Said Isse,1 Kota Vidyasagar,5 Kingsley Nnanna Ukwaja6 1Respiratory Institute Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates; 2Department of Pulmonology, Royal Hospital ...
Kota Vidyasagar, Wail A Tashkandi
exaly   +2 more sources

Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series

Journal of Allergy and Clinical Immunology: Global
Tezepelumab, a mAb targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations in severe asthma. Four cases in which patients with severe asthma and chronic rhinosinusitis with nasal polyps showed improvements in both conditions after receiving ...
Shigesato Inoue, MD, Hiroaki Ogata, MD, PhD, Yoichi Dotake, MD, Koichi Takagi, MD, PhD, Ayaka Shiota, MD, Yumiko Ishii, MD, PhD, Kentaro Tanaka, MD, PhD, Keiko Kan-o, MD, PhD, Hiromasa Inoue, MD, PhD   +8 more
doaj   +2 more sources

Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy

International Journal of Molecular Sciences
Thymic stromal lymphopoietin (TSLP), is a protein belonging to a class of epithelial cytokines commonly called alarmins, which also includes IL-25 and IL-33. Functionally, TSLP is a key player in the immune response to environmental insults, initiating a
Diego Bagnasco, Fulvio Braido, Laura de Ferrari   +2 more
exaly   +2 more sources

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types

Journal of Asthma and Allergy
Reynold Panettieri Jr,1 Njira Lugogo,2 Jonathan Corren,3 Christopher S Ambrose4 1Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, NJ, USA; 2Michigan Medicine Asthma Program, University of Michigan, Ann Arbor ...
Panettieri R Jr, Lugogo N, Corren J, Ambrose CS   +3 more
doaj   +2 more sources

Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort [PDF]

Frontiers in Allergy
BackgroundExertional symptom burden is an important yet insufficiently characterised component of morbidity in severe asthma. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations and improves asthma ...
Slagjana Stoshikj, Slagjana Stoshikj, Katharina Marth, Daniela Boryshchuk, Robin Ristl, Andreas Renner, Andreas Renner, Christina Bal, Christina Bal, Karin Patocka, Wolfgang Pohl, Karin Vonbank, Karin Vonbank, Marco Idzko, Marco Idzko   +14 more
doaj   +2 more sources